Table 2.
Hypertensive patients reclassified and recommended for treatment according to the 2017 ACC/AHA guideline
| Stage 1 hypertension | Stage 2 hypertension | Estimated number of hypertensive patients need to be pharmaceutically treated to reach the current treatment rate (43.4%) according to the 2018 Chinese guideline (mean, million) | |
|---|---|---|---|
| Untreated patients recommended for drug therapy (%) | Untreated patients recommended for drug therapy (%) | ||
| Overall | 22.7 (19.6‐25.8) | 21.1 (18.5‐23.6) | 32.1 (27.9‐36.2) |
| Age | |||
| 35‐44 | 6.0 (4.0‐7.9) | 8.8 (4.3‐13.4) | 3.2 (2.0‐4.3) |
| 45‐54 | 11.3 (9.1‐13.5) | 10.8 (8.9‐12.7) | 4.7 (4.1‐5.3) |
| 55‐64 | 40.1 (30‐50.1) | 16.3 (12.1‐20.5) | 8.9 (7.1‐10.5) |
| 65‐74 | 73.9 (60.3‐87.4) | 22.6 (16.7‐28.6) | 6.8 (5.7‐7.7) |
| ≥75a | 100.0 | 100.0 | 8.5 |
| P value | <0.001 | <0.001 | – |
| Sex | |||
| Men | 26.1 (21.5‐30.6) | 20.2 (18.0‐22.4) | 19.4 (17.8‐21.1) |
| Women | 18.4 (14.4‐22.3) | 22.2 (18.6‐25.8) | 12.7 (11.1‐14.3) |
| P value | 0.011 | 0.124 | – |
| Region | |||
| Eastern | 23.4 (16.2‐30.6) | 22.6 (19.4‐25.8) | 13.7 (11.3‐16.0) |
| Middle | 22.0 (18.6‐25.5) | 19.1 (12.7‐25.4) | 10.0 (8.3‐11.7) |
| Western | 22.5 (15.3‐29.7) | 21.2 (13.1‐29.4) | 8.3 (5.8‐10.7) |
| P value | 0.861 | 0.381 | – |
| Region | |||
| Urban | 21.0 (14.7‐27.3) | 21.5 (17.0‐25.9) | 10.1 (8.1‐12.1) |
| Rural | 23.5 (19.7‐27.3) | 20.9 (17.5‐24.3) | 21.9 (19.8‐24.1) |
| P value | 0.458 | 0.811 | – |
Data are presented as mean or percentage (95% CI). All values were weighted to represent the total population of Chinese aged 35 y or older based on the Chinese census 2010.
a
For those older than age 75, antihypertensive drugs are recommended for all hypertensive patients with systolic blood pressure ≥130 mm Hg or diastolic blood pressure ≥80 mm Hg.